<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; MDCO</title>
	<atom:link href="http://www.stockbloghub.com/tag/mdco/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(BJ) Company News for June 10, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/06/14/bj-company-news-for-june-10-2011-corporate-summary-2/76077</link>
		<comments>http://www.stockbloghub.com/2011/06/14/bj-company-news-for-june-10-2011-corporate-summary-2/76077#comments</comments>
		<pubDate>Tue, 14 Jun 2011 15:07:52 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Discount Variety Stores]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[3M Company]]></category>
		<category><![CDATA[BJ]]></category>
		<category><![CDATA[BJ's Wholesale Club Inc.]]></category>
		<category><![CDATA[Concho Resources Inc]]></category>
		<category><![CDATA[CXO]]></category>
		<category><![CDATA[DIS]]></category>
		<category><![CDATA[EEE]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Evergreen Energy Inc]]></category>
		<category><![CDATA[Hanesbrands Inc.]]></category>
		<category><![CDATA[HBI]]></category>
		<category><![CDATA[HLS Systems International Limited]]></category>
		<category><![CDATA[HOLI]]></category>
		<category><![CDATA[M]]></category>
		<category><![CDATA[Macy's Inc.]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[MMM]]></category>
		<category><![CDATA[Nasdaq OMX Group Inc]]></category>
		<category><![CDATA[NDAQ]]></category>
		<category><![CDATA[SJM]]></category>
		<category><![CDATA[The J. M. Smucker Company]]></category>
		<category><![CDATA[Titan Machinery Inc.]]></category>
		<category><![CDATA[TITN]]></category>
		<category><![CDATA[UBS]]></category>
		<category><![CDATA[UBS AG]]></category>
		<category><![CDATA[Walt Disney Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76077</guid>
		<description><![CDATA[•    On Thursday, 3M Company (NYSE:MMM) said it has concluded an agreement to buy manufacturer of quick cure, aircraft sealants Advanced Chemistry &#38; Technology. The acquisition will enhance and expand 3M&#8217;s product availability in the aerospace market •    Evergreen Energy Inc. (NYSE:EEE) said it has completed the formation of its venture with Australian listed mineral resources company WPG Resources. K-Fuel is Evergreen&#8217;s coal upgrading technology •    Titan Machinery Inc. (NASDAQ:TITN) reported Q1 EPS of $0.40, ahead of the Zacks Consensus Estimate of $0.23 per share. Revenues grew 54.9% year-over-year to $318.2 million, easily surpassing the Zacks Consensus Estimate of $245.0 million •    The J. M. Smucker Company (NYSE:SJM) reported Q4 EPS of $1.00 ex-items, marginally above the Zacks Consensus Estimate of $0.98 per share. Revenue for the quarter grew 11% ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/14/bj-company-news-for-june-10-2011-corporate-summary-2/76077/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BJ) Company News for June 10, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/06/10/bj-company-news-for-june-10-2011-corporate-summary/75980</link>
		<comments>http://www.stockbloghub.com/2011/06/10/bj-company-news-for-june-10-2011-corporate-summary/75980#comments</comments>
		<pubDate>Fri, 10 Jun 2011 15:55:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Discount Variety Stores]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[3M Company]]></category>
		<category><![CDATA[BJ]]></category>
		<category><![CDATA[BJ's Wholesale Club Inc.]]></category>
		<category><![CDATA[Concho Resources Inc]]></category>
		<category><![CDATA[CXO]]></category>
		<category><![CDATA[DIS]]></category>
		<category><![CDATA[EEE]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Evergreen Energy Inc]]></category>
		<category><![CDATA[Hanesbrands Inc.]]></category>
		<category><![CDATA[HBI]]></category>
		<category><![CDATA[HLS Systems International Limited]]></category>
		<category><![CDATA[HOLI]]></category>
		<category><![CDATA[M]]></category>
		<category><![CDATA[Macy's Inc.]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[MMM]]></category>
		<category><![CDATA[Nasdaq OMX Group Inc]]></category>
		<category><![CDATA[NDAQ]]></category>
		<category><![CDATA[SJM]]></category>
		<category><![CDATA[The J. M. Smucker Company]]></category>
		<category><![CDATA[Titan Machinery Inc.]]></category>
		<category><![CDATA[TITN]]></category>
		<category><![CDATA[UBS]]></category>
		<category><![CDATA[UBS AG]]></category>
		<category><![CDATA[Walt Disney Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=75980</guid>
		<description><![CDATA[•    On Thursday, 3M Company (NYSE:MMM) said it has concluded an agreement to buy manufacturer of quick cure, aircraft sealants Advanced Chemistry &#38; Technology. The acquisition will enhance and expand 3M&#8217;s product availability in the aerospace market •    Evergreen Energy Inc. (NYSE:EEE) said it has completed the formation of its venture with Australian listed mineral resources company WPG Resources. K-Fuel is Evergreen&#8217;s coal upgrading technology •    Titan Machinery Inc. (NASDAQ:TITN) reported Q1 EPS of $0.40, ahead of the Zacks Consensus Estimate of $0.23 per share. Revenues grew 54.9% year-over-year to $318.2 million, easily surpassing the Zacks Consensus Estimate of $245.0 million •    The J. M. Smucker Company (NYSE:SJM) reported Q4 EPS of $1.00 ex-items, marginally above the Zacks Consensus Estimate of $0.98 per share. Revenue for the quarter grew 11% ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/10/bj-company-news-for-june-10-2011-corporate-summary/75980/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDCO) The Medicines Company Analyst Reiterates Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/05/27/mdco-the-medicines-company-analyst-reiterates-neutral-on-shares/75058</link>
		<comments>http://www.stockbloghub.com/2011/05/27/mdco-the-medicines-company-analyst-reiterates-neutral-on-shares/75058#comments</comments>
		<pubDate>Fri, 27 May 2011 13:41:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PowerShares Autonomic Gr NFA Gbl Asset]]></category>
		<category><![CDATA[PTO]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=75058</guid>
		<description><![CDATA[We recently reiterated a Neutral recommendation on The Medicines Company (MDCO), which carries a Zacks #3 Rank (short-term Hold rating). The Medicines Company reported a first-quarter profit of 60 cents per share, well above the Zacks Consensus Estimate of 39 cents and the year-ago profit of 19 cents. Performance was boosted by higher revenues. Revenues, up 9.8% at $112.1 million, surpassed the Zacks Consensus Estimate of $110 million. The Medicines Company’s lead product, Angiomax (bivalirudin), is a specific and reversible direct thrombin inhibitor that was launched in early 2001. Despite the challenging economic scenario which has led to hospitals and patients cutting down on costly procedures, Angiomax sales in the first quarter of 2011 were up 9.7% year over year in the US. The Medicines Company received a major boost ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/27/mdco-the-medicines-company-analyst-reiterates-neutral-on-shares/75058/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDCO) The Medicines Company Reports Fourth Quarter Earnings Beat</title>
		<link>http://www.stockbloghub.com/2011/02/22/mdco-the-medicines-company-reports-fourth-quarter-earnings-beat/67288</link>
		<comments>http://www.stockbloghub.com/2011/02/22/mdco-the-medicines-company-reports-fourth-quarter-earnings-beat/67288#comments</comments>
		<pubDate>Tue, 22 Feb 2011 17:50:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67288</guid>
		<description><![CDATA[The Medicines Company (MDCO) reported a fourth-quarter profit of 27 cents per share, including the impact of stock-based compensation expense. Fourth quarter profit exceeded the Zacks Consensus Estimate of 24 cents and the year-ago loss of 57 cents. Performance was boosted by higher revenues and lower operating expenses. Revenues, up 17.3% at $119.6 million, surpassed the Zacks Consensus Estimate of $111 million. Full-year earnings came in at $1.15 per share, in-line with the Zacks Consensus Estimate and well above the year-ago loss of 46 cents. Full year revenues increased 8.3% to $437.6 million, well above the Zacks Consensus Estimate of $429 million. The Quarter in Detail Angiomax continued to see strong demand during the quarter with US sales increasing 16.3% to $112 million. US sales benefited from continued demand in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/02/22/mdco-the-medicines-company-reports-fourth-quarter-earnings-beat/67288/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDCO) The Medicines Company Receives Good Patent News</title>
		<link>http://www.stockbloghub.com/2010/12/10/mdco-the-medicines-company-receives-good-patent-news/61847</link>
		<comments>http://www.stockbloghub.com/2010/12/10/mdco-the-medicines-company-receives-good-patent-news/61847#comments</comments>
		<pubDate>Fri, 10 Dec 2010 20:18:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=61847</guid>
		<description><![CDATA[We recently reiterated our Outperform recommendation on The Medicines Company (MDCO). In August 2010, The Medicines Company received good news with the US District Court for the Eastern District of Virginia ordering the US Patent and Trademark Office (PTO) to treat The Medicines Company’s patent term extension application for lead product, Angiomax, as having been filed on a timely basis. Following this ruling, the PTO granted a one-year interim extension of the principal US patent that covers Angiomax. The extension will provide exclusivity until August 13, 2011 (February 2012 including 6-month pediatric exclusivity). With the US Solicitor General and the Government deciding against appealing the Court’s ruling, a major overhang on The Medicines Company has been removed. Previously, we were expecting Angiomax to start facing generics from late 2010. But, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/10/mdco-the-medicines-company-receives-good-patent-news/61847/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Industry Outlook &#8211; November 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687</link>
		<comments>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687#comments</comments>
		<pubDate>Mon, 15 Nov 2010 18:56:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=58687</guid>
		<description><![CDATA[With 2010 coming to an end, the pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. In fact, 2011 itself will see products worth more than $30 billion losing patent protection. This includes products like Lipitor, Plavix, Zyprexa and Levaquin. According to IMS Health, these products generated more than $17 billion ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDCO) The Medicines Company Earnings Well Above on Lower Costs</title>
		<link>http://www.stockbloghub.com/2010/11/03/mdco-the-medicines-company-earnings-well-above-on-lower-costs/56953</link>
		<comments>http://www.stockbloghub.com/2010/11/03/mdco-the-medicines-company-earnings-well-above-on-lower-costs/56953#comments</comments>
		<pubDate>Wed, 03 Nov 2010 15:34:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=56953</guid>
		<description><![CDATA[The Medicines Company (MDCO) reported a third-quarter profit of 40 cents per share Incorporatedluding the impact of stock-based compensation expense. Third quarter profit was well above the Zacks Consensus Estimate of 24 cents and the year-ago loss of 6 cents. Performance was boosted by higher revenues and lower operating expenses. Revenues, although up 6.9% at $105.7 million, fell short of the Zacks Consensus Estimate of $110 million. The Quarter in Detail Angiomax continued to see strong demand during the quarter. Angiomax sales in the US increased 9% to $100.2 million with Angiomax box sales increasing 14% from the year-ago period. EU sales increased 38% to $4 million mainly due to strong growth in countries like Italy, Switzerland, Spain, France, Scandinavia, and the United Kingdom. RoW sales, however, declined 42% to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/03/mdco-the-medicines-company-earnings-well-above-on-lower-costs/56953/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDCO) The Medicines Company Shares Uppgraded to Outperform</title>
		<link>http://www.stockbloghub.com/2010/10/12/mdco-the-medicines-company-shares-uppgraded-to-outperform/54526</link>
		<comments>http://www.stockbloghub.com/2010/10/12/mdco-the-medicines-company-shares-uppgraded-to-outperform/54526#comments</comments>
		<pubDate>Tue, 12 Oct 2010 14:29:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=54526</guid>
		<description><![CDATA[We recently upgraded The Medicines Company (MDCO) to Outperform based on our improved outlook on the stock. In August 2010, The Medicines Company received good news when the US District Court for the Eastern District of Virginia ordered the US Patent and Trademark Office (PTO) to treat the company’s patent term extension application for lead product Angiomax as having been filed on a timely basis. Following this ruling, the PTO granted a one-year interim extension of the principal US patent that covers Angiomax. The extension will provide exclusivity until August 13, 2011 (February 2012 including 6-month pediatric exclusivity). With the US Solicitor General and the Government deciding against appealing the Court’s ruling, a major overhang on The Medicines Company has been removed. Previously, we were expecting Angiomax to start facing ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/12/mdco-the-medicines-company-shares-uppgraded-to-outperform/54526/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDCO) The Medicines Company &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2010/10/11/mdco-the-medicines-company-bull-of-the-day/54611</link>
		<comments>http://www.stockbloghub.com/2010/10/11/mdco-the-medicines-company-bull-of-the-day/54611#comments</comments>
		<pubDate>Mon, 11 Oct 2010 15:19:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=54611</guid>
		<description><![CDATA[The Medicines Co. (MDCO) reported second-quarter EPS of $0.29, well above the Zacks Consensus Estimate and the year-ago EPS. Performance was boosted by higher revenues and lower operating expenses. Revenues increased 5.7%. The company received a major boost in August regarding its Angiomax patent extension case. The US Patent and Trademark Office has extended the principal patent on Angiomax by a year to August 2011, and has been instructed to treat the patent extension application as having been filed on a timely basis. We are also pleased to see that management is actively pursuing in-licensing deals and acquisitions to drive growth. Based on the improved outlook, we are upgrading the stock to Outperform. MEDICINES CO (MDCO): Free Stock Analysis Report Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/11/mdco-the-medicines-company-bull-of-the-day/54611/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDCO) Medicines Company Tops Street Estimates</title>
		<link>http://www.stockbloghub.com/2010/07/29/mdco-medicines-company-tops-street-estimates/45219</link>
		<comments>http://www.stockbloghub.com/2010/07/29/mdco-medicines-company-tops-street-estimates/45219#comments</comments>
		<pubDate>Fri, 30 Jul 2010 03:39:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=45219</guid>
		<description><![CDATA[The Medicines Co. (MDCO) reported a second-quarter profit of 27 cents per share Incorporatedluding the impact of stock-based compensation expense. Second quarter profit was well above the Zacks Consensus Estimate of 23 cents and the year-ago earnings of 8 cents. Performance was boosted by higher revenues and lower operating expenses. The company completed its cost reduction program by cutting more than 100 jobs and expects to achieve annual savings in the range of $14.5 million–$16.5 million. Meanwhile, revenues increased 5.7% to $110.1 million, $3 million above the Zacks Consensus Estimate. Angiomax continued to see strong demand during the quarter. While Angiomax sales in the US increased 5.7% to $104.4 million, sales in ex-US markets increased to $5.8 million. Strong growth in countries like Italy, France, Scandinavia, Benelux and the United ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/29/mdco-medicines-company-tops-street-estimates/45219/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Pharma and Biotech Industry Outlook &#8211; July 2010 &#8211; Analyst Interviews</title>
		<link>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204</link>
		<comments>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204#comments</comments>
		<pubDate>Mon, 26 Jul 2010 14:58:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[ABII]]></category>
		<category><![CDATA[Abraxis Bioscience Inc]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44204</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to cost-cutting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Pharma and Biotech Industry Outlook &#8211; July 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146</link>
		<comments>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146#comments</comments>
		<pubDate>Wed, 21 Jul 2010 03:08:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[ABII]]></category>
		<category><![CDATA[Abraxis Bioscience Inc]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44146</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to cost-cutting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDCO) The Medicines Company Gives Angiomax Update</title>
		<link>http://www.stockbloghub.com/2010/05/24/mdco-the-medicines-company-gives-angiomax-update/38226</link>
		<comments>http://www.stockbloghub.com/2010/05/24/mdco-the-medicines-company-gives-angiomax-update/38226#comments</comments>
		<pubDate>Tue, 25 May 2010 03:48:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=38226</guid>
		<description><![CDATA[The Medicines Company (MDCO) recently announced that the US District Court for the Eastern District of Virginia has ordered the US Patent and Trademark Office (PTO) to take necessary actions so as to make sure that the company’s patent on Angiomax does not expire until 10 days after the court issues a final order in an ongoing litigation. The order was passed related to a lawsuit filed by the Medicines Company against the PTO, the US Food and Drug Administration (FDA) and the US Department of Health and Human Services. The Medicines Company has applied to the court to set aside the PTO’s latest denial of the company’s patent extension application for Angiomax. The PTO had denied The Medicines Co.’s application and granted an interim extension of the patent until ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/24/mdco-the-medicines-company-gives-angiomax-update/38226/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Pharma &amp; Biotech Stock Review &#8211; April 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/04/29/abt-pharma-biotech-stock-review-april-2010-industry-outlook/35472</link>
		<comments>http://www.stockbloghub.com/2010/04/29/abt-pharma-biotech-stock-review-april-2010-industry-outlook/35472#comments</comments>
		<pubDate>Thu, 29 Apr 2010 14:10:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MIL]]></category>
		<category><![CDATA[Millipore Corporation]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[OSI Pharmaceuticals Inc]]></category>
		<category><![CDATA[OSIP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=35472</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/29/abt-pharma-biotech-stock-review-april-2010-industry-outlook/35472/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDCO) The Medicines Co. Challenges U.S. Patent and Trademark Office Decision</title>
		<link>http://www.stockbloghub.com/2010/03/29/mdco-the-medicines-co-challenges-u-s-patent-and-trademark-office-decision/32182</link>
		<comments>http://www.stockbloghub.com/2010/03/29/mdco-the-medicines-co-challenges-u-s-patent-and-trademark-office-decision/32182#comments</comments>
		<pubDate>Mon, 29 Mar 2010 20:10:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32182</guid>
		<description><![CDATA[In a continued attempt to get its Angiomax patent extended, The Medicines Co. (MDCO) recently filed yet another lawsuit against the U.S. Patent and Trademark Office (PTO), the U.S. Food and Drug Administration (FDA) and the U.S. Department of Health and Human Services. This time, the company has applied to the court to set aside the PTO’s recent denial of the company’s patent extension application. Last week, the PTO rejected The Medicines Co.’s application and granted an interim extension of the patent until May 23, 2010 (November including 6-months pediatric exclusivity). The Medicines Co. is asking the court to ignore this denial and direct the PTO to accept its patent term extension application as having been filed on a timely basis. Moreover, the company wants the court to order the PTO ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/29/mdco-the-medicines-co-challenges-u-s-patent-and-trademark-office-decision/32182/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDCO) The Medicines Company&#8217;s Patent Extension Denied</title>
		<link>http://www.stockbloghub.com/2010/03/25/mdco-the-medicines-companys-patent-extension-denied/31437</link>
		<comments>http://www.stockbloghub.com/2010/03/25/mdco-the-medicines-companys-patent-extension-denied/31437#comments</comments>
		<pubDate>Thu, 25 Mar 2010 19:37:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[PowerShares Autonomic Gr NFA Gbl Asset]]></category>
		<category><![CDATA[PTO]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31437</guid>
		<description><![CDATA[A couple of days after The Medicines Co. (MDCO) received a breather in the form of a favorable court order in its lawsuit against the U.S. Patent and Trademark Office (PTO), the U.S. Food and Drug Administration (FDA) and the U.S. Department of Health and Human Services, the company suffered a setback when the PTO once again refused to extend its patent for key product, Angiomax. The Medicines Company is seeking to extend the term of its principal US patent for Angiomax, which is scheduled to expire on Mar 23, 2010 (Sep 23, 2010 including six-month pediatric exclusivity). The Medicines Company filed for Hatch-Watchman exclusivity way back in 2001. However, the patent extension request was filed a day late due to confusion related to the approval date for Angiomax. Since ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/25/mdco-the-medicines-companys-patent-extension-denied/31437/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDCO) The Medicines Company&#8217;s Patent Extension is Denied</title>
		<link>http://www.stockbloghub.com/2010/03/23/mdco-the-medicines-companys-patent-extension-is-denied/31492</link>
		<comments>http://www.stockbloghub.com/2010/03/23/mdco-the-medicines-companys-patent-extension-is-denied/31492#comments</comments>
		<pubDate>Tue, 23 Mar 2010 17:51:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31492</guid>
		<description><![CDATA[A couple of days after The Medicines Company (MDCO) received a breather in the form of a favorable court order in its lawsuit against the U.S. Patent and Trademark Office (PTO), the U.S. Food and Drug Administration (FDA) and the U.S. Department of Health and Human Services, the company suffered a setback when the PTO once again refused to extend The Medicines Company’s patent for key product, Angiomax. The Medicines Company is seeking to extend the term of its principal US patent for Angiomax, which is scheduled to expire on March 23, 2010 (September 23, 2010 including six-month pediatric exclusivity). The company had filed for Hatch-Watchman exclusivity way back in 2001. However, the patent extension request was filed a day late due to confusion related to the approval date for ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/23/mdco-the-medicines-companys-patent-extension-is-denied/31492/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDCO) The Medicines Company Wins Favorable Court Order</title>
		<link>http://www.stockbloghub.com/2010/03/18/mdco-the-medicines-company-wins-favorable-court-order/31215</link>
		<comments>http://www.stockbloghub.com/2010/03/18/mdco-the-medicines-company-wins-favorable-court-order/31215#comments</comments>
		<pubDate>Thu, 18 Mar 2010 20:23:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31215</guid>
		<description><![CDATA[The Medicines Company (MDCO) received a much needed breather recently in the form of a favorable order issued by the U.S. District Court for the Eastern District of Virginia in the company&#8217;s lawsuit against the U.S. Patent and Trademark Office (PTO), the U.S. Food and Drug Administration (FDA) and the U.S. Department of Health and Human Services. The Medicines Company is seeking to extend the term of its principal US patent for its lead product, Angiomax, which is scheduled to expire on March 23, 2010 (September 23, 2010 including six-month pediatric exclusivity). Although The Medicines Company filed for Hatch-Watchman exclusivity in 2001, the patent extension request was filed a day late due to confusion related to the approval date for Angiomax. Since then, The Medicines Company has been petitioning the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/18/mdco-the-medicines-company-wins-favorable-court-order/31215/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RX) Pharma &amp; Biotech Stock Review &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/01/29/rx-pharma-biotech-stock-review-industry-outlook/26385</link>
		<comments>http://www.stockbloghub.com/2010/01/29/rx-pharma-biotech-stock-review-industry-outlook/26385#comments</comments>
		<pubDate>Sat, 30 Jan 2010 00:08:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[IMS Health Inc.]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RX]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26385</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health (RX), this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Seretide. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to cost-cutting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/29/rx-pharma-biotech-stock-review-industry-outlook/26385/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDCO) The Medicines Company is Upgraded to Neutral</title>
		<link>http://www.stockbloghub.com/2010/01/04/mdco-the-medicines-company-is-upgraded-to-neutral/24076</link>
		<comments>http://www.stockbloghub.com/2010/01/04/mdco-the-medicines-company-is-upgraded-to-neutral/24076#comments</comments>
		<pubDate>Mon, 04 Jan 2010 18:09:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24076</guid>
		<description><![CDATA[We recently upgraded our recommendation on The Medicines Company (MDCO) to Neutral from Underperform. Despite the economic slowdown and cost-cutting by hospitals, The Medicines Company’s lead product Angiomax continues to perform well. We expect Angiomax sales to remain strong with The Medicines Company continuing to present encouraging data. Moreover, new guidelines issued by the American College of Cardiology / American Heart Association (ACC/AHA) supporting the use of Angiomax should help boost product sales. Meanwhile, we are also pleased to see that Angiomax (trade name: Angiox) is performing well in Europe. Sales in Europe are beginning to benefit from trial data demonstrating the economic and clinical benefits of Angiomax/Angiox. We expect a slow but steady ramp in international Angiomax/Angiox sales over the next few quarters. The Medicines Company recently received positive ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/04/mdco-the-medicines-company-is-upgraded-to-neutral/24076/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDCO) The Medicines Co Recalls Cleviprex Lots</title>
		<link>http://www.stockbloghub.com/2009/12/18/mdco-the-medicines-co-recalls-cleviprex-lots/23222</link>
		<comments>http://www.stockbloghub.com/2009/12/18/mdco-the-medicines-co-recalls-cleviprex-lots/23222#comments</comments>
		<pubDate>Sat, 19 Dec 2009 00:04:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23222</guid>
		<description><![CDATA[The Medicines Co. (MDCO) recently announced the voluntary recall of eleven lots of Cleviprex (clevidipine butyrate) injectable emulsion. During a routine annual inspection, the presence of visible particulate matter was observed in some vials. However, The Medicines Co. stated that it has not yet received any product complaints or reports of adverse events associated with the issue. Physicians have, nevertheless, been warned to inspect the vials before using the product. The Medicines Company received approval for Cleviprex in August 2008 for the short-term control of blood pressure in patients undergoing cardiac surgery. The product is an ultra-short acting calcium channel blocker (CCB) given intravenously when oral therapy is not feasible or desirable. The drug acts by selectively relaxing the smooth muscle cells that line small arteries, resulting in widening of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/18/mdco-the-medicines-co-recalls-cleviprex-lots/23222/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDCO) The Medicines Company Gets Angiox Label Expanded</title>
		<link>http://www.stockbloghub.com/2009/12/03/mdco-the-medicines-company-gets-angiox-label-expanded/21848</link>
		<comments>http://www.stockbloghub.com/2009/12/03/mdco-the-medicines-company-gets-angiox-label-expanded/21848#comments</comments>
		<pubDate>Thu, 03 Dec 2009 22:55:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21848</guid>
		<description><![CDATA[The Medicines Company (MDCO) recently received positive news in the form of a label expansion for Angiox in the EU. The European Commission granted approval for the use of Angiox as an anticoagulant in patients with heart attacks [ST-segment elevation myocardial infarction (STEMI)] undergoing emergency heart procedures called primary percutaneous coronary intervention (PCI). The approval was expected as Angiox received a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) in Oct 2009. The approval was based on the landmark HORIZONS-AMI study which demonstrated a reduction in deaths from heart attacks in patients undergoing emergency PCI. The trial showed that patients treated with Angiox compared with heparin plus a platelet glycoprotein IIb/IIIa inhibitor (GPI) were more likely to survive and had ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/03/mdco-the-medicines-company-gets-angiox-label-expanded/21848/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDCO) The Medicines Company &#8211; Bear of the Day</title>
		<link>http://www.stockbloghub.com/2009/11/29/mdco-the-medicines-company-bear-of-the-day/21407</link>
		<comments>http://www.stockbloghub.com/2009/11/29/mdco-the-medicines-company-bear-of-the-day/21407#comments</comments>
		<pubDate>Mon, 30 Nov 2009 04:47:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21407</guid>
		<description><![CDATA[The Medicines Company&#8216;s (MDCO) third-quarter loss per share of 6 cents missed the Zacks Consensus Estimate of a loss of 5 cents. Although Angiomax continues to contribute significantly to revenues, we are concerned about the product losing exclusivity in the U.S. in September 2010. The entry of generics would be devastating for the company. Therefore, the onus is on management to acquire and develop the next generation of products to drive the top-line. One of those products was expected to be Cangrelor. However, the failure of the phase III CHAMPION program was a significant setback. Meanwhile, the Cleviprex sales ramp has also been slow. We recommend avoiding the name until we gain more visibility on the Angiomax patent situation, the Cleviprex ramp and the future of Cangrelor and Oritavancin. Zacks ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/29/mdco-the-medicines-company-bear-of-the-day/21407/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDCO) Medicines Company &#8211; Bear of the Day</title>
		<link>http://www.stockbloghub.com/2009/11/19/mdco-medicines-company-bear-of-the-day/20919</link>
		<comments>http://www.stockbloghub.com/2009/11/19/mdco-medicines-company-bear-of-the-day/20919#comments</comments>
		<pubDate>Thu, 19 Nov 2009 20:44:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20919</guid>
		<description><![CDATA[The Medicines Company&#8217;s (MDCO) third-quarter loss per share of 6 cents missed the Zacks Consensus Estimate of a loss of 5 cents. Although Angiomax continues to contribute significantly to revenues, we are concerned about the product losing exclusivity in the U.S. in September 2010. The entry of generics would be devastating for the company. Therefore, the onus is on management to acquire and develop the next generation of products to drive the top-line. One of those products was expected to be Cangrelor. However, the failure of the phase III CHAMPION program was a significant setback. Meanwhile, the Cleviprex sales ramp has also been slow. We recommend avoiding the name until we gain more visibility on the Angiomax patent situation, the Cleviprex ramp and the future of Cangrelor and Oritavancin. Zacks ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/19/mdco-medicines-company-bear-of-the-day/20919/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDCO) Medicines Co. Misses Forecasts &amp; Cuts Projections</title>
		<link>http://www.stockbloghub.com/2009/11/02/mdco-medicines-co-misses-forecasts-cuts-projections/19419</link>
		<comments>http://www.stockbloghub.com/2009/11/02/mdco-medicines-co-misses-forecasts-cuts-projections/19419#comments</comments>
		<pubDate>Mon, 02 Nov 2009 21:40:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19419</guid>
		<description><![CDATA[Medicines Co.’s (MDCO) third-quarter loss per share of 6 cents missed the Zacks Consensus Estimate of a loss of 5 cents. Revenues increased 12% to $98.8 million from $88.13 million in the year ago period driven by strong sales of Angiomax (bivalirudin). Angiomax, the lead product of the company that was acquired from Biogen Idec, Inc. (BIIB) in 1996, is used as an anticoagulant in patients undergoing coronary angioplasty. The drug recorded robust sales growth compared to the year ago period – 9% to $92.2 million and 74% to $5.5 million in both domestic and international market, respectively. The only other drug of Medicines Co., Cleviprex (clevidipine), received US Food and Drug Administration (FDA) approval in 2008. It is an intravenous drug (calcium channel blocker) intended for the short-term control ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/02/mdco-medicines-co-misses-forecasts-cuts-projections/19419/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDCO) Medicines Company&#8217;s Angiomax Anti-Clotting Drug Promising</title>
		<link>http://www.stockbloghub.com/2009/09/02/mdco-gpi-medicines-companys-angiomax-anti-clotting-drug-promising/14136</link>
		<comments>http://www.stockbloghub.com/2009/09/02/mdco-gpi-medicines-companys-angiomax-anti-clotting-drug-promising/14136#comments</comments>
		<pubDate>Wed, 02 Sep 2009 20:44:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Co]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14136</guid>
		<description><![CDATA[Medicines Co. (MDCO) yesterday presented encouraging results from its landmark HORIZONS-AMI study on anti-clotting drug, Angiomax. The company stated that treatment with Angiomax resulted in improved survival rates in patients who had suffered from the most severe form of heart attack and received angioplasty. Approximately 3,600 patients with ST elevation myocardial infarction (STEMI), the most severe form of acute heart attack, and undergoing primary percutaneous coronary intervention (PCI), commonly known as angioplasty, were studied in the trial. Patients were randomized to receive Angiomax with provisional use of a glycoprotein IIb/IIIa inhibitor or heparin plus a glycoprotein IIb/IIIa inhibitor. Results showed that Angiomax reduced cardiac-related death by 43%, improved overall survival by 27% and reduced major bleeding complications by 39%, compared to the standard of care. Angiomax showed an absolute reduction ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/02/mdco-gpi-medicines-companys-angiomax-anti-clotting-drug-promising/14136/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

